• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    XTL Biopharmaceuticals Ltd. (XTLB)

    -NasdaqCM
    2.13 Down 0.08(3.62%) Dec 26, 2:14PM EST
    Add to Portfolio
    ProfileGet Profile for:
    XTL Biopharmaceuticals Ltd.
    Building G
    Herzliya Business Park
    Herzliya, 46140
    Israel - Map
    Phone: 972 9 955 7080
    Fax: 972 9 951 9727
    Website: http://www.xtlbio.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:12

    Business Summary 

    XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. The company’s lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Its rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases with focus on schizophrenia. It has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is based in Herzliya, Israel.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on XTL Biopharmaceuticals Ltd.

    Key Executives 
     PayExercised
    Mr. Joshua Levine , 49
    Chief Exec. Officer and Director
    N/AN/A
    Mr. David Kestenbaum , 49
    Chief Financial Officer
    N/AN/A
    Mr. Ronen Kantor Adv ,
    Company Sec.
    N/AN/A
    Prof. Moshe Mittelman , 61
    Medical Director
    N/AN/A
    Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders